- Home
- APPS vs ANAB Comparison
APPS vs ANAB Comparison
Compare APPS & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APPS
- ANAB
- Stock Information
- Founded
- APPS 2007
- ANAB 2005
- Country
- APPS United States
- ANAB United States
- Employees
- APPS N/A
- ANAB N/A
- Industry
- APPS Multi-Sector Companies
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- APPS Miscellaneous
- ANAB Health Care
- Exchange
- APPS Nasdaq
- ANAB Nasdaq
- Market Cap
- APPS 555.2M
- ANAB 621.1M
- IPO Year
- APPS N/A
- ANAB 2017
- Fundamental
- Price
- APPS $5.76
- ANAB $23.17
- Analyst Decision
- APPS Hold
- ANAB Buy
- Analyst Count
- APPS 3
- ANAB 10
- Target Price
- APPS $3.33
- ANAB $44.25
- AVG Volume (30 Days)
- APPS 9.7M
- ANAB 760.3K
- Earning Date
- APPS 06-16-2025
- ANAB 08-04-2025
- Dividend Yield
- APPS N/A
- ANAB N/A
- EPS Growth
- APPS N/A
- ANAB N/A
- EPS
- APPS N/A
- ANAB N/A
- Revenue
- APPS $490,506,000.00
- ANAB $111,872,000.00
- Revenue This Year
- APPS $9.10
- ANAB N/A
- Revenue Next Year
- APPS $8.12
- ANAB $24.39
- P/E Ratio
- APPS N/A
- ANAB N/A
- Revenue Growth
- APPS N/A
- ANAB 387.20
- 52 Week Low
- APPS $1.18
- ANAB $12.21
- 52 Week High
- APPS $7.77
- ANAB $41.31
- Technical
- Relative Strength Index (RSI)
- APPS 56.32
- ANAB 56.01
- Support Level
- APPS $4.55
- ANAB $22.46
- Resistance Level
- APPS $5.46
- ANAB $24.17
- Average True Range (ATR)
- APPS 0.74
- ANAB 1.72
- MACD
- APPS 0.10
- ANAB -0.01
- Stochastic Oscillator
- APPS 44.34
- ANAB 73.23
About APPS Digital Turbine Inc.
Digital Turbine Inc is an independent mobile growth platform. It offers end-to-end products and solutions to all participants in the mobile application ecosystem, enabling brand discovery and advertising, user acquisition and engagement, and operational efficiency for advertisers. Its operating segments are On Device Solutions and App Growth Platform.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).